Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

645.05INR
22 May 2018
Change (% chg)

Rs18.20 (+2.90%)
Prev Close
Rs626.85
Open
Rs628.00
Day's High
Rs649.90
Day's Low
Rs616.40
Volume
1,927,693
Avg. Vol
2,755,469
52-wk High
Rs677.90
52-wk Low
Rs295.03

Chart for

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  BION.NS Industry Sector
P/E (TTM): -- 222.84 32.59
EPS (TTM): -- -- --
ROI: -- -7.75 12.60
ROE: -- -10.55 14.49

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

02 May 2018

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

26 Apr 2018

India's Biocon Q4 profit rises 2.2 pct

April 26 Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

26 Apr 2018

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

11 Apr 2018

BRIEF-Mylan, Biocon get approvals from European Commission, TGA Australia for Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE APPROVALS FROM THE EUROPEAN COMMISSION AND TGA AUSTRALIA FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE Source text for Eikon: Further company coverage:

28 Mar 2018

BRIEF-India's Biocon ‍Says U.S. FDA Completed Pre-Approval Inspection At Malaysia Unit ​

* ‍U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT MALAYSIA FACILITY AND ISSUED FORM 483 WITH 6 OBSERVATIONS​ Source text - http://bit.ly/2EUL56I Further company coverage:

21 Feb 2018

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

15 Feb 2018

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

29 Jan 2018

India's Biocon Q3 profit plunges 46 pct

Jan 24 Biocon Ltd, India's biggest biotechnology firm, posted a 46 percent fall in third-quarter profit on Wednesday hurt by an increase in interest and depreciation costs related to its Malaysia operations.

24 Jan 2018

BRIEF-India's Biocon Dec-Qtr Consol Profit Down About 46 pct

* DEC QUARTER CONSOL PROFIT 919 MILLION RUPEES VERSUS 1.71 BILLION RUPEES LAST YEAR

24 Jan 2018

Earnings vs. Estimates

No consensus analysis data available.